Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin in Dravet syndrome
NCT04572243Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lorcaserin in Dravet syndrome, sponsored by Eisai Co., Ltd.. Started Sep 2020; status: terminated.
02
Drugs
lorcaserin
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT04572243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572243.